Ultra‐low‐molecular‐weight heparin vs placebo
Major bleeding · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes onlyRR 1.05 [0.55, 2]1 study · 3172 participantsModerate